scholarly journals Cholinergic stimulation of vasopressin release in spontaneously hypertensive rats.

Hypertension ◽  
1984 ◽  
Vol 6 (6_pt_1) ◽  
pp. 855-860 ◽  
Author(s):  
C D Sladek ◽  
M L Blair
2020 ◽  
Vol 47 (7) ◽  
pp. 1254-1262
Author(s):  
Takahiro Shimizu ◽  
Masaki Yamamoto ◽  
Suo Zou ◽  
Shogo Shimizu ◽  
Youichirou Higashi ◽  
...  

2020 ◽  
Vol 34 (S1) ◽  
pp. 1-1
Author(s):  
Pamela Nithzi Bricher Choque ◽  
Maria Helena Mattos Porter ◽  
Luiz Fernando Pereira ◽  
Humberto Dellè ◽  
Maria Claudia Irigoyen ◽  
...  

2003 ◽  
Vol 9 (3) ◽  
pp. 102-106
Author(s):  
Yu. I. Shcherbin ◽  
R. S. Khrustaleva ◽  
V. A. Cirlin

In chloralose anesthetized and paralyzed spontaneously hypertensive rats (SHR) a somatosympathetic reflex in the cervical sympathetic trunk elicited by a single electrical shock to forelimb afferent fibres in the median nerve was recorded. It has been shown that the somatosympathetic reflex consists of two responses and following silent period. The А-response evoked by the somatic myelinated afferent fibres stimulation, and C-respon.se elicited by the both stimulation of myelinated and unmyelinated afferent fibres. The silent period occurred with the myelinated fibres stimulation. Its duration was proportional to the electrical shock amplitude. The А-response consisted of four waves, the three of them formed early and late responses.


2020 ◽  
Vol 318 (1) ◽  
pp. H124-H134 ◽  
Author(s):  
Zhi Geng ◽  
Chao Ye ◽  
Ying Tong ◽  
Feng Zhang ◽  
Ye-Bo Zhou ◽  
...  

Elabela (ELA) is a newly discovered peptide that acts as a novel endogenous ligand of angiotensin receptor-like 1 (APJ) receptor. This study was designed to evaluate the effects of ELA-21 in paraventricular nucleus (PVN) on blood pressure and sympathetic nerve activity in spontaneously hypertensive rats (SHR). Experiments were performed in male Wistar-Kyoto rats (WKY) and SHR. ELA expression was upregulated in PVN of SHR. PVN microinjection of ELA-21 increased renal sympathetic nerve activity (RSNA), mean arterial pressure (MAP), heart rate (HR), plasma norepinephrine, and arginine vasopressin (AVP) levels in SHR. Intravenous injection of ELA-21 significantly decreased MAP and HR in both WKY and SHR, but only induced a slight decrease in RSNA. APJ antagonist F13A in PVN abolished the effects of ELA-21 on RSNA, MAP and HR. Intravenous infusion of both ganglionic blocker hexamethonium and AVP V1a receptor antagonist SR49059 caused significant reduction in the effects of ELA-21 on RSNA, MAP and HR in SHR, while combined administration of hexamethonium and SR49059 abolished the effects of ELA-21. ELA-21 microinjection stimulated Akt and p85α subunit of phosphatidylinositol 3-kinase (PI3K) phosphorylation in PVN, whereas PI3K inhibitor LY294002 or Akt inhibitor MK-2206 almost abolished the effects of ELA-21 on RSNA, MAP, and HR. Chronic PVN infusion of ELA-21 induced sympathetic activation, hypertension, and AVP release accompanied with cardiovascular remodeling in normotensive WKY. In conclusion, ELA-21 in PVN induces exacerbated pressor and sympathoexcitatory effects in hypertensive rats via PI3K-Akt pathway. NEW & NOTEWORTHY We demonstrated that PVN microinjection of ELA-21 increases sympathetic nerve activity and blood pressure, which can be abolished by pretreatment of APJ antagonist. This is the first demonstration that central ELA can induce hypertension. The pressor effects in PVN are mediated by both sympathetic activation and vasopressin release via PI3K-Akt pathway. Our data confirm that ELA is upregulated in the PVN of SHR and so may be involved in the pressor and sympathoexcitatory effects in hypertension.


2015 ◽  
Vol 193 ◽  
pp. 97-103 ◽  
Author(s):  
João H.D. Blanco ◽  
Ada C. Gastaldi ◽  
Camila B. Gardim ◽  
João E. Araujo ◽  
Marcus V. Simões ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Camila B. Gardim ◽  
Ana Catarine Veiga ◽  
Bruno A. Aguilar ◽  
Stella V. Philbois ◽  
Hugo C. D. Souza

AbstractWe investigated hemodynamic, cardiac morphofunctional, and cardiovascular autonomic adaptations in spontaneously hypertensive rats (SHRs) after aerobic physical training associated with chronic cholinergic stimulation. Fifty-four SHRs were divided into two groups: trained and untrained. Each group was further subdivided into three smaller groups: vehicle, treated with pyridostigmine bromide at 5 mg/kg/day, and treated with pyridostigmine bromide at 15 mg/kg/day. The following protocols were assessed: echocardiography, autonomic double pharmacological blockade, heart rate variability (HRV), blood pressure variability (BPV), and baroreflex sensitivity (BRS). Physical training and pyridostigmine bromide reduced BP and HR and increased vagal participation in cardiac autonomic tonic balance. The associated responses were then potentialized. Treatment with pyridostigmine bromide increased HRV oscillation of both low frequency (LF: 0.2–0.75 Hz) and high frequency (HF: 0.75–3 Hz). However, the association with physical training attenuated HF oscillations. Additionally, treatment with pyridostigmine bromide also increased LF oscillations of BPV. Both treatment groups promoted morphofunctional adaptations, and associated increased ejection volume, ejection fraction, cardiac output, and cardiac index. In conclusion, the association of pyridostigmine bromide and physical training promoted greater benefits in hemodynamic parameters and increased vagal influence on cardiac autonomic tonic balance. Nonetheless, treatment with pyridostigmine bromide alone seems to negatively affect BPV and the association of treatment negatively influences HRV.


Sign in / Sign up

Export Citation Format

Share Document